Building strategic partnerships to advance clinical excellence - our recent collaboration with Sharehereon Health has opened doors to high-quality refractory cancer care at Parkway Shanghai Hospital.
On 1 November, Parkway Shanghai Hospital partnered Professor Ding Gang, Founder of Sharehereon Health, to launch the Parkway Shanghai Hospital Oncology Center and Parkway International Refractory Oncology Consultation Center. This strategic collaboration unifies the expertise and resources of both healthcare organisations to deliver better oncology diagnosis and treatment for cancer patients.
“This strategic partnership is a harbinger of more great things to come. Refractory cancer, which is the cancer resistant to standard treatment, is a high potential segment in the private healthcare space and there’s great promise in it cementing our domain expertise in oncology,” shared Dr Prem Kumar Nair, Group CEO of IHH Healthcare, during his opening address.
Buoyed by this new development, IHH China will continue to innovate clinical practices, foster multidisciplinary cooperation and prioritise holistic patient care, to bring hope and improved outcomes to more cancer patients in Shanghai.
Related Stories
Project Renaissance at Mount Elizabeth Hospital, Where Legacy Meets the Future of Care
Over a span of 1,095 days, Project Renaissance marked a significant chapter in the evolution of Mount Elizabeth Hospital, one of Singapore’s most established private healthcare institutions. Conceived as a strategic transformation rather than a conventional refurbishment, the initiative sought to position the hospital for the demands of a rapidly changing healthcare landscape.
IHH Healthcare North Asia Strengthens Integrated Care Through Strategic Partnership
IHH Malaysia Partners Libyan Government for Medical Referrals
IHH Healthcare Malaysia signed a Memorandum of Understanding (MOU) with The Government of Libya on 9 February, establishing a structured medical referral pathway for Libyan civil servants requiring specialist treatment at 18 hospitals across IHH’s Malaysian network.
Agilus Diagnostics Expands Access to Next-Generation Precision Genomics
Agilus Diagnostics, a subsidiary of Fortis Healthcare, has installed the Illumina NovaSeq X sequencing platform at its Mumbai reference laboratory, marking a major step forward for precision genomics in India.
Parkway Shanghai Opens International Centre for Hepatobiliary and Pancreatic Diseases
